



Commercial and Diagnostic Kits Paragraph 7.5, ICH M10 draft

Breakout Workshop Moderator – Arno Kromminga, on behalf of the EBF



- Commercial or diagnostic kits are sometimes co-developed with new drugs or therapeutic biological products for point-of-care patient diagnosis.
- <u>Repurposes kits</u> to measure chemical or biological drug concentrations during the development of a novel drug.
- The recommendations in this section of the guideline do not apply to the development of kits that are intended for point-of-care patient diagnosis (e.g., companion or complimentary diagnostic kits).



- Identify challenges and agree on proposed recommendations for change on the paragraph
- We will split into 7 key areas
 - 1. Validation criteria
 - 2. Standards
 - 3. Quality controls
 - 4. Matrix
 - 5. Lot-to-lot variability
 - 6. Inter plate variability
 - 7. Have we missed something?



➤ Tuesday, 21 May 2019, 8:30 - 10:00

Room: URANO